Company / SG&A Expense
Ernexa Therapeutics Inc. SG&A Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$13.1M
FY2025
5-year range
$13.1M / $16.8M
FY2021-FY2025
Trend
-10.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $13M in FY2025 to $18M in FY2015.
Based on SEC 10-K filings.
$13M in FY2025 with a 10-year CAGR of -3.3%.
Improved from $17M to $13M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -0.1%
- 10-Year CAGR
- -3.3%
Key checks
Key Insights
- 5-year CAGR of -0.1%, indicating a declining trend.
- In FY2025, sg&a expense decreased 10.0% year-over-year.
- Peak sg&a expense was recorded in FY2015.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.1M | -10.0% |
| FY2024 | $14.6M | -13.4% |
| FY2023 | $16.8M | +27.8% |
| FY2020 | $13.2M | -8.9% |
| FY2019 | $14.5M | -7.2% |
| FY2018 | $15.6M | -5.3% |
| FY2017 | $16.5M | -8.9% |
| FY2016 | $18.1M | -1.7% |
| FY2015 | $18.4M | +13.2% |
| FY2014 | $16.2M | -11.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026